Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial.

ABSTRACT: The development of an effective vaccine against SARS-CoV-2 marks one of the highest priorities during the ongoing pandemic. However, recruitment of participants for clinical trials can be challenging, and recruitment failure is among the most common reasons for discontinuation in clinical trials. From 20 May 2020, public announcements about a planned phase I trial of the vaccine candidate MVA-SARS-2-S against SARS-CoV-2 began, and interested individuals started contacting the study team via designated e-mail. All emails received from these individuals between 20 May 2020-30 September 2020 were assessed. Of the 2541 interested volunteers, 62% contacted the study team within three days after the first media announcement. The average age was 61 years (range 16-100), 48% of volunteers were fem

SUBMITTER: Shamsrizi P 

PROVIDER: S-EPMC8538230 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature